Literature DB >> 31949828

microRNA-134 inhibits melanoma growth and metastasis by negatively regulating collagen triple helix repeat containing-1 (CTHRC1).

Yuan Li1, Yong Fu2, Yu Gao1, Haiying Li1, Lei Ma1, Chunmen Shu1, Na Li1, Chong Ma3.   

Abstract

Melanoma, a malignant tumor of melanocytes, is considered to be the most aggressive of skin cancers and its incidence keeps increasing worldwide. miR-134 and CTHRC1 have been demonstrated to be involved in the occurrence and development of various tumors. However, their roles are still elusive in the progression of melanoma. qRT-PCR and western blot (WB) were used to examine the expressions of miR-134 and CTHRC1 in clinical specimens of melanoma patients and melanoma cell lines. Dual-luciferase reporter assay was applied to verify the target interaction between miR-134 and CTHRC1. The mRNA and protein expressions of CTHRC1 were measured by qRT-PCR and WB after treatment by miR-134 inhibitor and mimic. Subsequently, CCK8, colony formation assay, and flow cytometry were utilized to assess the influences of miR-134 and CTHRC1 on cell growth of melanoma. Cell migration and invasion experiments were performed to evaluate the effects of miR-134 and CTHRC1 on metastasis of melanoma. It was shown that CTHRC1 was up-regulated and miR-134 was down-regulated in melanoma patients and cell lines. CTHRC1 was demonstrated to be a direct target of miR-134. Ultimately, we also found that up-regulated miR-134 expression and down-regulated CTHRC1 expression could suppress cell proliferation and cell colony formation, promote apoptosis, delay the cell cycle, and hinder cell migration and invasion. Our findings suggest that miR-134 could inhibit the growth and metastasis of melanoma by negatively regulating CTHRC1. IJCEP
Copyright © 2018.

Entities:  

Keywords:  CTHRC1; cell metastasis; cell migration; melanoma; miR-134

Year:  2018        PMID: 31949828      PMCID: PMC6962948     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  23 in total

Review 1.  MicroRNAs and RNA binding protein regulators of microRNAs in the control of pluripotency and reprogramming.

Authors:  Jing Hao; Fei-Fei Duan; Yangming Wang
Journal:  Curr Opin Genet Dev       Date:  2017-07-25       Impact factor: 5.578

2.  Evidence for soluble factors regulating cell death and cell proliferation in primary cultures of rabbit endometrial cells grown on collagen.

Authors:  M P Lynch; S Nawaz; L E Gerschenson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

3.  MicroRNA-134 suppresses endometrial cancer stem cells by targeting POGLUT1 and Notch pathway proteins.

Authors:  Yongtao Gao; Te Liu; Yongyi Huang
Journal:  FEBS Lett       Date:  2014-12-17       Impact factor: 4.124

4.  MicroRNA-134 targets KRAS to suppress breast cancer cell proliferation, migration and invasion.

Authors:  Xiaomei Su; Ling Zhang; Hua Li; Peng Cheng; Yajie Zhu; Zhen Liu; Yu Zhao; Hongyu Xu; Dong Li; Hui Gao; Tao Zhang
Journal:  Oncol Lett       Date:  2017-01-25       Impact factor: 2.967

5.  Melanoma incidence rises for children and adolescents: an epidemiologic review of pediatric melanoma in the United States.

Authors:  Mary T Austin; Yan Xing; Andrea A Hayes-Jordan; Kevin P Lally; Janice N Cormier
Journal:  J Pediatr Surg       Date:  2013-11       Impact factor: 2.545

Review 6.  Melanoma in children and adolescents.

Authors:  A S Pappo
Journal:  Eur J Cancer       Date:  2003-12       Impact factor: 9.162

Review 7.  Epigenetic regulation in human melanoma: past and future.

Authors:  Debina Sarkar; Euphemia Y Leung; Bruce C Baguley; Graeme J Finlay; Marjan E Askarian-Amiri
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

Review 8.  MicroRNAs in melanoma development and resistance to target therapy.

Authors:  Luigi Fattore; Susan Costantini; Debora Malpicci; Ciro Francesco Ruggiero; Paolo Antonio Ascierto; Carlo M Croce; Rita Mancini; Gennaro Ciliberto
Journal:  Oncotarget       Date:  2017-03-28

Review 9.  miR-134: A Human Cancer Suppressor?

Authors:  Jing-Yu Pan; Feng Zhang; Cheng-Cao Sun; Shu-Jun Li; Guang Li; Feng-Yun Gong; Tao Bo; Jing He; Rui-Xi Hua; Wei-Dong Hu; Zhan-Peng Yuan; Xin Wang; Qi-Qiang He; De-Jia Li
Journal:  Mol Ther Nucleic Acids       Date:  2016-12-10

Review 10.  Current status and perspectives in immunotherapy for metastatic melanoma.

Authors:  Riccardo Marconcini; Francesco Spagnolo; Luigia Stefania Stucci; Simone Ribero; Elena Marra; Francesco De Rosa; Virginia Picasso; Lorenza Di Guardo; Carolina Cimminiello; Stefano Cavalieri; Laura Orgiano; Enrica Tanda; Laura Spano; Alfredo Falcone; Paola Queirolo
Journal:  Oncotarget       Date:  2018-01-03
View more
  3 in total

Review 1.  MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

2.  The microRNA miR-134-5p induces calcium deposition by inhibiting histone deacetylase 5 in vascular smooth muscle cells.

Authors:  Nakwon Choe; Sera Shin; Hosouk Joung; Juhee Ryu; Young-Kook Kim; Youngkeun Ahn; Hyun Kook; Duk-Hwa Kwon
Journal:  J Cell Mol Med       Date:  2020-08-11       Impact factor: 5.310

3.  miR-509-3p Suppresses Migration, Invasion, and Epithelial- Mesenchymal Transition in Melanoma Cells by Targeting Collagen Triple Helix Repeat Containing 1.

Authors:  Keyu Yuan; Yi Sun; Yu Ji
Journal:  Balkan Med J       Date:  2021-05       Impact factor: 2.021

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.